지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 32 - 40 (9page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy. This study evaluated the feasibility and therapeutic efficacy of metronomic chemotherapy in patients with advanced hepatocellular carcinoma (HCC) with major portal vein thrombosis (PVT). Methods: Thirty consecutive HCC patients with major PVT with or without extrahepatic metastasis were prospectively allocated to metronomic chemotherapy consisting of epirubicin being infused through the correct hepatic artery at a dose of 30 mg/body surface area (BSA) every 4 weeks, and cisplatin (15 mg/BSA) and 5-fluorouracil (50 mg/BSA) every week for 3 weeks, with intervening 1 week breaks. The treatment response was assessed using response evaluation criteria in solid tumors (RECIST). Results: In total, 116 cycles of metronomic chemotherapy were administered to the 30 patients,with a median of 3 cycles given to individual patients (range, 1-15 cycles). Six patients (20.0%) achieved a partial response and six patients (20.0%) had stable disease. The median time to disease progression and overall survival were 63 days (range, 26-631 days) and 162 days (95% confidence interval; range, 62-262 days), respectively. Overall survival was significantly associated with baseline alpha-fetoprotein level (P=0.001) and tumor response (P=0.005). The baseline alpha-fetoprotein level was significantly associated with the disease control rate (P=0.007). Adverse events were tolerable and managed successfully with conservative treatment. Conclusions: Metronomic chemotherapy may be a safe and useful palliative treatment in HCC patients with major PVT. (Korean J Hepatol 2012;18:32-40)
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Ando E / 2002 / Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases / Cancer 95 : 588 ~ 595
Bertolini F / 2003 / Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor
Bocci G / 2003 / Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy / Proc Natl Acad Sci U S A 100 : 12917 ~ 12922
Boucher E / 2002 / Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen) / Canc
Browder T / 2000 / Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer / Cancer Res 60 : 1878 ~ 1886
Bertolini F / 2003 / Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor
Bocci G / 2003 / Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy / Proc Natl Acad Sci U S A 100 : 12917 ~ 12922
Boucher E / 2002 / Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen) / Canc
Browder T / 2000 / Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer / Cancer Res 60 : 1878 ~ 1886
이 논문의 저자 정보
최근 본 자료
댓글(0)
0